Recce Enters Second U.S. Department of Defense R&D Agreement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The study will evaluate the gel's effectiveness in reducing bacterial burden in burn wounds, particularly against significant pathogens associated with infections. The gel is designed to provide rapid, broad-spectrum anti-infective action and aims to address the urgent need for new treatments for burn wound infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- AUD $5.3m R&D Rebate Received
- RCE Awarded Advanced Overseas Finding up to A$85m
- Hong Kong Patent Granted for RECCE Anti-Infectives
- Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
Later from Recce Pharmaceuticals
- Appendix 4D and Interim Financial Report
- RCE Investor Webinar Presentation Deck
- Brazil Patent Granted for RECCE Anti-Infectives
- Recce Signs Middle East Licensing Term Sheet
- Addendum to Recce Signs Middle East Licensing Term Sheet
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals